<DOC>
	<DOCNO>NCT02428660</DOCNO>
	<brief_summary>This randomize controlled trial evaluate whether use pharmacogenetic test Medication Therapy Management ( MTM ) program beneficial impact drug therapy problem . More specifically , cytochrome DNA testing , provide information regard participant specific metabolism medication , use evaluation participant medication regimen . The overall aim project evaluate addition genetic CYP test standardized MTM Program provide increase clinical value . To answer question , investigator look drug therapy problem ( DTPs ) identify genetic test compare DTPs discover without test .</brief_summary>
	<brief_title>Drug &amp; Gene Interaction Risk Analysis With &amp; Without Genetic Testing Among Patients Undergoing MTM</brief_title>
	<detailed_description>All study participant receive Comprehensive Medication Review ( CMR ) . One third standard MTM conduct . Another third participant randomize MTM plus drug interaction risk analysis via YouScript software . The remain third randomize MTM along drug interaction risk analysis via YouScript software genetic testing . The software identify polypharmacy patient may benefit pharmacogenetic test base current medication regimen . Results test mailed participant provider . Participants undergo test also receive follow-up phone call . All participant , include receive MTM alone , receive contact 3 month later assess quality life .</detailed_description>
	<mesh_term>Metabolism , Inborn Errors</mesh_term>
	<criteria>Aged 65 enrol Medicare PartD Prescription Drug Plan . Currently prescribe ≥6 chronic medication . Have ≥3 chronic disease state include osteoarthritis , rheumatoid arthritis , heart failure , diabetes , dyslipidemia , hypertension , asthma , chronic obstructive pulmonary disease , atrial fibrillation , coronary artery disease . Participant incur Medicaremandated dollar amount medicationrelated cost previous quarter . Inability perform MTM encounter due living situation ( e.g . patient enrol hospice , long term care facility ) . Patient unable perform MTM encounter due metal health barrier describe Brief Interview Mental Status ( BIMS ) score &lt; 13 point . Patient identifies unable perform oral swab function genetic test . Patient know MTM session within precede 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Polypharmacy</keyword>
	<keyword>Chronic condition</keyword>
	<keyword>Drug Therapy Problems</keyword>
	<keyword>Medication Therapy Management</keyword>
	<keyword>Medication-Related Problems</keyword>
	<keyword>CYP3A4</keyword>
	<keyword>CYP3A5</keyword>
	<keyword>Drug-drug interaction</keyword>
	<keyword>Drug-gene interaction</keyword>
	<keyword>Drug-drug-gene interaction</keyword>
	<keyword>Adverse Drug Reactions</keyword>
	<keyword>Activities Daily Living</keyword>
</DOC>